Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis

[1]  M. Beksac,et al.  Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. , 2021, The New England journal of medicine.

[2]  P. Hawkins,et al.  Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real‐world longitudinal data , 2021, British journal of haematology.

[3]  A. Wechalekar,et al.  Epidemiologic and Survival Trends in Amyloidosis, 1987-2019. , 2020, The New England journal of medicine.

[4]  M. Mohty,et al.  Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk , 2019, Haematologica.

[5]  P. Hawkins,et al.  A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. , 2019, Blood.

[6]  D. Dingli,et al.  Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis , 2019, Leukemia.

[7]  C. Varga,et al.  In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival , 2019, Blood.

[8]  A. Foli,et al.  Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. , 2018, Blood.

[9]  A. Krishnan,et al.  Early Relapse after Autologous Hematopoietic Cell Transplantation remains a Poor Prognostic Factor in Multiple Myeloma but Outcomes Have Improved Over Time , 2017, Leukemia.

[10]  D. Hose,et al.  Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. , 2016, Blood.

[11]  D. Dingli,et al.  Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents , 2016, Leukemia.

[12]  R. Falk,et al.  Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis , 2012, Leukemia.

[13]  M. Dimopoulos,et al.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Dingli,et al.  Impact of early relapse after auto-SCT for multiple myeloma , 2008, Bone Marrow Transplantation.

[15]  D. Dingli,et al.  Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. , 2011, Mayo Clinic proceedings.